Year :

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

SOMERSET, N.J.— (BUSINESS WIRE)—August 4, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang “Frank” Zhang as Class II director […]

Aug 04, 2022

Legend Biotech Corporation Announces Proposed Public Offering (July 25, 2022)

SOMERSET, NJ – July 25, 2022 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering. All […]

Jul 25, 2022

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

SOMERSET, N.J.— (BUSINESS WIRE) —April 21, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the achievement of a $50 million milestone under its collaboration agreement with Janssen Biotech, Inc. (Janssen) for ciltacabtagene autoleucel (cilta-cel), now marketed in the United […]

Apr 21, 2022

Legend Biotech Announces Appointment of Global Head of Research and Early Development

SOMERSET, N.J.— (BUSINESS WIRE) —April 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development. Dr. Guowei Fang is an accomplished scientist and […]

Apr 01, 2022

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Ciltacabtagene autoleucel, if approved by the European Commission (EC), will be Legend Biotech’s first EC-approved product SOMERSET, N.J.— (BUSINESS WIRE) —March 25, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use […]

Mar 25, 2022

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.